ACR Appropriateness Criteria® Osteoporosis and Bone Mineral Density: 2022 Update

Yu, Joseph S.; Krishna, Nidhi G.; Fox, Michael G.; Blankenbaker, Donna G.; Frick, Matthew A.; Jawetz, Shari T.; Li, Guibin; Reitman, Charles A.; Said, Nicholas; Stensby, J. Derek; Subhas, Naveen; Tülchinsky, Mark; Walker, Eric A.; Beaman, Francesca D.

doi:10.1016/j.jacr.2022.09.007

Cited by 23 publications

(8 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alternatively, volumetric BMD (mg/cm 3 ) can be directly measured by QCT. Of the 2 methods, central DXA is generally preferred for making therapeutic decisions and limiting radiation exposure, however, QCT may be considered superior to DXA in settings of severe degenerative disease or scoliosis [ 147 ]. A number of studies have suggested that fracture risk can also be assessed with CT attenuation in Hounsfield units (HU), which can be measured from CT scans obtained for other purposes that include the lumbar spine (opportunistic bone density measurement).…”

Section: Resultsmentioning

confidence: 99%

The influence of osteoporosis on mechanical complications in lumbar fusion surgery: a systematic review

Filley,

Baldwin,

Ben-Natan

et al. 2024

North American Spine Society Journal (NASSJ)

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

The influence of osteoporosis on mechanical complications in lumbar fusion surgery: a systematic review

Filley,

Baldwin,

Ben-Natan

et al. 2024

North American Spine Society Journal (NASSJ)

View full text Add to dashboard Cite

“…Exploring new causes of osteoporosis has important clinical signi cance for the prevention and treatment of osteoporosis. Especially the latest guideline has included hip and vertebral fragility fractures as diagnostic criteria for osteoporosis, without the need to test their T-values, resulting in a signi cant increase in the number of osteoporosis patients worldwide [10]. Therefore, early screening for PMO is particularly important.…”

Section: Discussionmentioning

confidence: 99%

miR-595/Cldnd1 axis: a potential risk factor for bone loss in postmenopausal women with hip osteoporotic fracture

Jingyue,

Peixin,

Xiao

2024

Preprint

View full text Add to dashboard Cite

Background Recently researches have reported that miRNA and its target genes are associated with osteoporosis. MiRNAs/mRNA axis might be an potential diagnostic marker for osteoporosis. Purposes The aim of this study is to explore the potential miRNA and mRNA markers by bioinformatics method and clinical analysis. Patients and Methods The miRNA expression profiles were obtained from GSE74209, GSE64433 and GSE115773 in Gene expression Omnibus (GEO). The mRNA expression profiles were obtained from GSE100609. Wayne intersection were used to explore the different expressed miRNAs (DE-miRs). Select the miRNA with the highest Fold Change for subsequent research. Screening of miRNA target genes using TargetScan and miRDB tools. GO and KEGG analyses of target genes (TGs) function were performed. Validate the selected TGs in the GSE100609. We collected female patients with femural intertrochanteric fractures from July 1, 2023 to October 31, 2023. Patient's bone marrow and clinical data were collected. MiRNA and the target mRNA differentially expressed in bone marrow were verified through RT-qPCR. All data were subjected to Shapiro-Wilk test. Using Pearson or Spearman test to detect the correlation between various indicators, and then incorporating indicators related to bone density into multiple linear regression equations. Partial correlation analysis was used to analyze the correlation between the final indicators and bone density. Results A total of 140 DE-miRs were identified between high bone density and low bone density women. Set the fold change to “>1” and ultimately include 5 miRNAs. Using miR-595 (highest |log2 FC|) as the subject of subsequent research. 3542 targeted mRNAs were predicted from TargetScan and 362 were from miRDB. 337 TGs were intersected, which were mainly enriched in nucleus. Only Cldnd1 were identified using the GSE100609 dataset. We found that miR-595 was highly expressed in patients with high bone mass, while its target gene Cldnd1 was downregulated. There was a strong collinearity between miR-595 and Cldnd1. Further multiple linear regression analysis showed a high correlation between miR-595 and bone density. Conclusions These data suggest that Cldnd1 might be a downstream factor of miR-595. miR-595/Cldnd1 axis might be an independent risk factor for decreased bone mass.

show abstract

“…The former included: PsA disease duration, PsO onset, family history of PsA/PsO, diagnostic delay (the time between onset of symptoms and date of PsA diagnosis) and smoking habit. The clinical assessment included: joint involvement subtype (oligo-or poly-arthritis), axial involvement [34] (yes/no), enthesitis [35] (yes/no), dactylitis [36] (yes/no), cutaneous PsO (yes/no), PASI (Psoriasis Area Severity Index) score, nail PsO (yes/no) and the presence of any of the following comorbidities: cardio-vascular accidents (CVA) [37], chronic obstructive pulmonary disease (COPD) [37], malignancies [37], chronic kidney disease (CKF) [37], cardio-vascular risk factors [38] as arterial hypertension (AH), mellitus diabetes (MD), metabolic syndrome (MeS), hyperlipaemia [39], depression (diagnosed by a specialist), bromyalgia [40], osteoporosis [41] and hyperuricemia ( 7mg/ml).…”

Section: Methodsmentioning

confidence: 99%

How do we treat psoriatic arthritis in the era of GRAPPA recommendations: predictive factors for bDMARDs usage in PsA patients in a real life setting

Ferraioli,

Conigliaro,

Fatica

et al. 2023

Preprint

View full text Add to dashboard Cite

Psoriatic arthritis’s therapeutic approach has recently improved, as indicated by the recent GRAPPA recommendations, since the introduction of bDMARDs with different targets. Purpose of this study was to evaluate usage of PsA recommendations for bDMARDs selection based on baseline predictive factors. A retrospective study was conducted on bDMARD-naïve patients, in stable condition. Study population was divided in two groups based on the period they started treatment: between January 2006-December 2013 and between January 2014-December 2022. Then, impact of clinical PsA features and comorbidities was evaluated as an influencing factor in bDMARD selection. 146 patients were included in the 1st period (all receiving TNFi) and 250 in the 2nd (175 received TNFi and 75 ILi). Comparing only TNFi treated patients, subjects treated in the 2nd period presented less frequently PsO, enthesitis, poly-arthritis, bone erosions, CV risk factors, while those presenting PsO familiarity, oligo-arthritis and axial involvement resulted more frequently treated. Comparisons of patients treated in 2nd period with TNFi and ILi resulted that those presenting PsO, nail PsO, axial involvement and CV risk factors were more frequently treated with ILi while those presenting bone erosions with TNFi. Therefore, it is possible to speculate that PsA clinical features/comorbidities may influence treatment choices.

show abstract

ACR Appropriateness Criteria® Osteoporosis and Bone Mineral Density: 2022 Update

Cited by 23 publications

References 106 publications

The influence of osteoporosis on mechanical complications in lumbar fusion surgery: a systematic review

The influence of osteoporosis on mechanical complications in lumbar fusion surgery: a systematic review

miR-595/Cldnd1 axis: a potential risk factor for bone loss in postmenopausal women with hip osteoporotic fracture

How do we treat psoriatic arthritis in the era of GRAPPA recommendations: predictive factors for bDMARDs usage in PsA patients in a real life setting

Contact Info

Product

Resources

About